Trials soon ready
Clinical trials expected to report results within the next 6 months, ranked by how much the coming result could matter. Each trial shows its estimated finish date, explained in plain language.
This page shows companies working on cures and vaccines first, on purpose. We believe investor interest in cures leads to more cure trials. Why we do this.
Showing the top 50 of 162 trials in this window.
Results due in the coming weeks
These trials are in their final phase, the companies running them are on the stock market, and results are due within weeks. A final-phase result is usually the last big test before a treatment can be approved, and it can move the company's value in either direction. We list them up top so you see the nearest dates first.
-
Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread Results expected Sep 2026 (estimated) 🚀 Make-or-breakClarity Pharmaceuticals Ltd ASX: CU6
-
New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
Rabies vaccine batch check: will it pass the test? Results expected Sep 2026 (estimated) 🚀 Make-or-breakSinovac Biotech Co., Ltd. NASDAQ: SVA
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
Can a shorter radiation course spare the rectum in rectal cancer?
Cure OngoingThe hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly compare the newly established TNT concepts applying either short-course RT according to RAPIDO, or CRT according to CAO/ARO/AIO-04/-12, both followed by consolidation chemotherapy, and surgery or a watch\&wait…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Prof. Dr. med. Claus Rödel • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Could a Virus-Like particle vaccine outsmart polio?
Vaccine OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
Result impactVery highSmall-cap Phase 2 Readout in ~1 wkA small company. This result carries real weight for it.
CanSino Biologics Inc. · 6185 HKEXWhy investors are watching
CanSino Biologics is testing a new polio vaccine that uses virus-like particles instead of the traditional live or inactivated virus. This trial checks the vaccine's safety and immune response in infants and toddlers, and a positive result could give the small company a new product in a global market with steady demand. Because CanSino is small, this single trial's outcome can meaningfully affect its value and reputation.
If it works: A successful readout could position CanSino as a leader in next-generation polio vaccines, potentially opening partnerships or licensing deals with larger organizations. It may also validate the company's VLP platform for other vaccines, broadening its pipeline.
If it fails: The trial could fail to show adequate immune response or safety, which would set back the program and hurt investor confidence. Trials at this stage often fail, and any delay in enrollment or dosing could also weigh on the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Result impactModerateLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
Could a stem cell transplant cure immune diseases?
Cure Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can specially trained immune cells flush out hidden HIV?
Cure OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase 1 • Sponsor: Catherine Bollard • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with leukemia: smarter chemo dosing could boost cures
Cure OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Cure
Last updated Jul 18, 2026 00:00 UTC
-
Can a single radiation dose cure large liver tumors?
Cure Recruiting nowThe RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in pa…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lung cancer
Cure Recruiting nowA study to evaluate the safety and feasibility of α-PD-L1/4-1BB DLL3 Chimeric Antigen Receptor (CAR)-T (BHP01) in patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate CAR-T cell dose. Next, In dose expansion phase, patients were assign two…
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Sichuan University • Aim: Cure
Last updated Jul 23, 2026 00:00 UTC
-
Hepatitis b cure breakthrough? new combo aims for 50%+ cure rate
Cure Recruiting nowExploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overa…
Results expected Dec 2026 (estimated)
Phase 4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Cure
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Cure Recruiting nowThe purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. · 601607 SSEResult impactLowLarge company Readout in ~3 moA large company. One readout moves the needle only so far.
-
Major RSV vaccine trial for seniors nears completion
Vaccine OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
Can donor immune cells be engineered to fight blood cancer?
Cure Recruiting nowKCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.
Results expected Feb 2027 (estimated)
Phase 1 • Sponsor: University College, London • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Can a single injection reprogram immune cells to fight cancer?
Cure Recruiting nowThis is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with…
Results expected Mar 2027 (estimated)
Phase 1 • Sponsor: Ruijin Hospital • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can a single eye injection restore sight in genetic blindness?
Cure OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Results expected Mar 2027 (estimated)
Phase 1/2 • Sponsor: Ocugen • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~5 moA small company. This result carries real weight for it.
Ocugen · OCGN NASDAQ Trade on eToro (ad)Why investors are watching
Ocugen is a micro-cap company, so this Phase 1/2 trial of OCU400, a gene therapy for three inherited retinal diseases, is a core value driver. The trial tests safety and efficacy in 22 to 24 patients, and a positive readout could validate the therapy's broad approach across multiple mutations. For a company this size, the result of this small study carries outsized weight.
If it works: A positive safety and efficacy result could position OCU400 as a promising treatment for multiple forms of blindness, potentially attracting partners or funding. It could also support the company's path toward larger trials and eventual regulatory discussions.
If it fails: The trial could fail to show meaningful vision improvement or reveal safety problems, which would likely set the program back. Early-stage trials often fail, and a negative result for a micro-cap company could be severe, as the company has few other assets to fall back on.
AI-written from the trial record. Speculative, and not investment advice.
-
Engineered immune cells target CD5 in Hard-to-Treat T-Cell lymphomas
Cure Recruiting nowThis is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in …
Results expected Nov 2026 (estimated)
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Can a Three-Drug cocktail before surgery stop small cell lung cancer from returning?
Cure Recruiting nowThis is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer. Adebrelimab combined with chemotherapy for 4 cycles and apatinib mesylate for 3 cycles. Surgery was perform…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Jin Ying • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells target CD70 in kidney cancer
Cure OngoingThis is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~2 moA small company. This result carries real weight for it.
Adicet Bio · ACET NASDAQ Trade on eToro (ad)Why investors are watching
Adicet Bio runs this Phase 1/2 trial of ADI-270, an engineered gamma-delta CAR Vδ1 T cell therapy that targets CD70, in adults with relapsed or refractory clear cell renal cell carcinoma. The study tests dose escalation and dose expansion across 60 planned participants. For a micro-cap company, this readout carries the whole story: it is the main evidence that the platform works in patients.
If it works: A positive result could support further development of ADI-270 and draw partner or financing interest. It may also validate the company's engineered gamma-delta T cell approach beyond this one cancer.
If it fails: Early-phase trials often fail on safety, tolerability, or signs of benefit. A failure or delay could leave the company with limited clinical momentum and few other late-stage assets.
AI-written from the trial record. Speculative, and not investment advice.
-
Off-the-Shelf Gene-Edited immune cells tested against Hard-to-Treat lymphoma
Cure Recruiting nowThis is a single center, prospective, open-label, single-arm, phase 1/2 study for patients with r/r B-cell NHL to evaluate the safety and efficacy of gene edited allogenic CD19 CAR-γδT cells. The cells are from healthy adult volunteer donors that are gene edited ex vivo using CRI…
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Chinese PLA General Hospital • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Engineered t cells target FLT3 in Hard-to-Treat leukemia
Cure Recruiting nowThis is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable adult and 18 evaluable pediatric subjects will be enrolled. Evaluable subjects are defined as those who have …
Results expected Jan 2027 (estimated)
Phase 1 • Sponsor: Hemogenyx Pharmaceuticals LLC • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
Vaccine OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: Vaccine
Last updated Jul 08, 2026 00:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
Cure Recruiting nowEnrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFO…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
Cure Recruiting nowThis is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: New York Medical College • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
Aiming to cure esophageal cancer without the knife
Cure OngoingThe present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment o…
Results expected Jan 2027 (estimated)
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
New mRNA vaccine aims to stop the stomach flu
Vaccine OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~5 moA large company. One readout moves the needle only so far.
-
New chikungunya vaccine trial aims to protect millions
Vaccine Recruiting nowA Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: Bharat Biotech International Limited • Aim: Vaccine
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells take aim at Mesothelioma—Can they deliver?
Cure OngoingThis study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an M…
Results expected Sep 2026 (estimated)
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
New marburg vaccine trial aims to stop deadly virus
Vaccine OngoingA Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Results expected Oct 2026 (estimated)
Phase 2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: Vaccine
Last updated Sep 12, 2026 00:00 UTC
-
Can a Patient's own immune cells beat advanced kidney cancer?
Cure Not yet recruitingA Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting Preconditioning with Fludarabine and Cyclophosphamide and Subsequent Interleukin-2 Therapy in Patients with Advanc…
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
Vaccine OngoingThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: AstraZeneca • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~2 wkA large company. One readout moves the needle only so far.
-
New needle treatment could replace surgery for curing Hormone-Driven high blood pressure
Cure OngoingThe primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria. Secondary objectives are to …
Results expected Nov 2026 (estimated)
Sponsor: Queen Mary University of London • Aim: Cure
Last updated Jul 19, 2026 00:00 UTC
-
Promising malaria vaccine candidates enter key trial in african children
Vaccine OngoingThis is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 11:01 UTC
-
Pfizer gives lyme vaccine a fifth dose — will it boost protection?
Vaccine Recruiting nowThe purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactHighLarge company Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
Heat, not surgery: new trial aims to cure thyroid cancer without a knife
Cure Recruiting nowThis pilot, single-arm clinical study evaluates the feasibility, safety, and effectiveness of radiofrequency ablation (RFA) as a curative treatment for small, low-risk papillary thyroid cancer (PTC). The study will enroll 30 adult patients (≥18 years) with biopsy-confirmed PTC me…
Results expected Dec 2026 (estimated)
Sponsor: University Health Network, Toronto • Aim: Cure
Last updated Jun 27, 2026 12:35 UTC
-
HPV vaccine trial aims to protect women with HIV from cervical cancer
Vaccine OngoingHuman papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly infected. The main burden of HPV-related disease is…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Serum Institute of India Pvt. Ltd. • Aim: Vaccine
Last updated Jul 01, 2026 00:00 UTC
-
Personalized vaccine aims to train immune system against cancer
Vaccine By invitation onlyA Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Results expected Jan 2027 (estimated)
Phase 1/2 • Sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines • Aim: Vaccine
Last updated Jun 27, 2026 08:11 UTC
-
Can two immunotherapy drugs eliminate early rectal cancer without surgery?
Cure Recruiting nowThis is a multi-site, prospective, non-randomized phase 2 study evaluating neoadjuvant botensilimab in combination with balstilimab for patients with microsatellite stable (MSS) / mismatch repair proficient (MMRp) early rectal cancer staged T1-T2 N0 by MRI and considered candidat…
Results expected Jan 2027 (estimated)
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
Triple threat: new vaccine aims to tackle three salmonella strains at once
Vaccine OngoingThis is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.
Results expected Jan 2027 (estimated)
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Vaccine
Last updated Jul 01, 2026 00:00 UTC
-
New vaccine aims to shield sickle cell kids from deadly infections
Vaccine Recruiting nowThe purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 12:08 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New mRNA shot targets bird flu: 4,000 volunteers needed
Vaccine OngoingThe purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New malaria vaccine shows promise in african trial
Vaccine Recruiting nowThis is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa. The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double d…
Results expected Feb 2027 (estimated)
Phase 2 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Jun 27, 2026 13:01 UTC
-
New sudan ebola vaccine moves to phase 2 trial in healthy adults
Vaccine OngoingA Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Results expected Feb 2027 (estimated)
Phase 2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: Vaccine
Last updated Jun 27, 2026 09:03 UTC
-
Can a vaccine stop stomach cancer from coming back?
Cure OngoingThe purpose of this early proof-of-concept study to evaluate the safety and immunologic efficacy of AST-301 in gastric cancer patients with HER2 expression (including both HER2 low expression and overexpression) who have completed the standard adjuvant treatment (including those …
Results expected Feb 2027 (estimated)
Phase 2 • Sponsor: Aston Sci. Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~5 moA small company. This result carries real weight for it.
-
Two-Drug malaria punch targets faster cure in kids
Cure Recruiting nowThis was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Results expected Feb 2027 (estimated)
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Novartis AG · NVS NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~5 moA large company. One readout moves the needle only so far.
-
Can a Birth-Dose polio vaccine block the virus in Babies' guts?
Vaccine Recruiting nowThe study will compare the transmissible levels of poliovirus type-2 detected in stool samples collected at the time of the nOPV2 challenge and subsequent timepoints in 3 groups of newborns receiving an nOPV2 dose at birth and primed with 3 doses of IPV (6 - 10 - 14 weeks of age)…
Results expected Mar 2027 (estimated)
Phase 3 • Sponsor: Fidec Corporation • Aim: Vaccine
Last updated Sep 11, 2026 00:00 UTC
-
Can a vaccine shield children from severe hand, foot, and mouth disease?
Vaccine Not yet recruitingThe purpose of this study is to evaluate the immunogenicity and safety of an inactivated Enterovirus Type 71 (EV71) vaccine, manufactured by Sinovac, in healthy Vietnamese children aged 6 to 71 months. Hand, Foot, and Mouth Disease (HFMD) is a common infectious disease in childr…
Results expected Jan 2027 (estimated)
Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
Result impactHighSmall-cap Readout in ~4 moA small company. This result carries real weight for it.
Sinovac Biotech Co., Ltd. · SVA NASDAQWhy investors are watching
Sinovac is testing its inactivated EV71 vaccine in 320 healthy Vietnamese children aged 6 to 71 months. The trial measures whether the vaccine triggers a protective antibody response and checks for side effects over two months. For a small-cap company, this readout matters because it could extend the vaccine's market beyond China into Vietnam, where hand, foot, and mouth disease is a serious threat.
If it works: A positive result could support regulatory approval in Vietnam, opening a new revenue stream for Sinovac. It would also strengthen the vaccine's track record in a second Asian population, which may help future regional partnerships.
If it fails: If the vaccine fails to show adequate immunogenicity or raises safety concerns, Sinovac would lose the Vietnam opportunity and face reputational damage. Trials often fail, and a delay in enrollment or data readout could also stall the company's plans.
AI-written from the trial record. Speculative, and not investment advice.
-
New RSV vaccine aims to shield adults from severe respiratory infection
Vaccine Recruiting nowThe purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Aug 16, 2026 00:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
Electric pulses target prostate tumors while sparing healthy tissue
Cure Recruiting nowConventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the…
Results expected Jan 2027 (estimated)
Sponsor: Chinese University of Hong Kong • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
New RSV vaccine trial aims to protect vulnerable transplant recipients
Vaccine OngoingAdjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral an…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Vaccine
Last updated Jun 27, 2026 12:28 UTC
-
New 24-Valent vaccine aims to shield children from more pneumonia strains
Vaccine Recruiting nowA Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenici…
Results expected Sep 2026 (estimated)
Phase 2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:06 UTC
Result impactVery highSmall-cap Phase 2 Readout dueA small company. This result carries real weight for it.
Sinovac Biotech Ltd. · SVA NASDAQWhy investors are watching
Sinovac Biotech Ltd. is a small publicly traded company, and its unit Sinovac Life Sciences Co., Ltd. runs this Phase 2 trial of a 24-valent pneumococcal conjugate vaccine in children aged 2 months to 5 years. The trial tests whether the vaccine is safe and produces an immune response, comparing it against an existing positive control in 420 participants. For a company this size, a vaccine that covers more pneumococcal strains than current options would matter because pediatric vaccines sell in large, recurring public health markets.
If it works: If the vaccine proves safe and immunogenic, Sinovac could move it into later-stage trials and toward a product that competes in the pediatric pneumococcal vaccine market. A strong result may also draw partner or public health interest that a small company cannot generate on its own.
If it fails: Phase 2 trials often fail on safety or immune response, and a negative readout would end this program's path forward. A delay or weak result would cost the company time and money it may struggle to replace at its size.
AI-written from the trial record. Speculative, and not investment advice.
-
New vaccine aims to shield against deadly meningitis strains
Vaccine Recruiting nowPhase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: EyeGene Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:00 UTC
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so the "Listed companies" view shows only companies our broker partner carries; switch to all sponsors for the unfiltered list. Ranking is never for sale: no company can pay to appear here or to place higher.